{"entity":{"id":"nct06525350","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed","aka":[],"tldr":"A phase 2 trial of docetaxel in lung cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., not yet recruiting.","summary":"A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT06525350 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with a registry enrolment figure of 256 participants, started 2024-07 and due to reach its primary completion in 2026-12-25. Interventions recorded: Glumetinib tablets; HB1801 (docetaxel, albumin-bound）; Docetaxel. Conditions listed: Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression. Primary outcome: Dose-limiting toxicity(DLT) occurrence and incidence; Recommended phase 2 dose(RP2D) of the combination therapy; Adverse events (AE) and serious adverse events (SAE) occurrence and incidence. Lung eligibility wording from the registry: \"Unresectable locally advanced or metastatic non-small cell lung cancer (IIIB, IIIC, or IV according to the 8th edition TNM staging standards of IASLC) confirmed by histology or cytology;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06525350","url":"https://clinicaltrials.gov/study/NCT06525350"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["met-altered-nsclc","stage-iii-unresectable-nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["docetaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06525350","phase":"2","setting":"A Randomized, Controlled, Open-label Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of the Combination of Glumetinib Tablets and Docetaxel for Injection（Albumin Bound）Verse Docetaxel in the Treatment of Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer Patients With MET Overexpression","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","enrolled":256,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06525350/","neighbours":{"cancer":[{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}